Chisholm et al developed a nomogram for evaluating a patient with rhabdomyosarcoma in relapse. This can help to identify a patient who may benefit from salvage therapy. The authors are from Royal Marsden Hospital and multiple hospitals in Europe and South America.
Patient selection: recurrent rhabdomyosarcoma
Parameters:
(1) types of chemotherapy
(2) histology
(3) nodal status
(4) tumor site
(5) tumor size in cm
(6) type of recurrence
(7) history of radiation therapy
(8) time to relapse
|
Parameter |
Finding |
Points |
|
type of chemotherapy |
2 drug |
83.2 |
|
|
3 drug |
0 |
|
|
6 drug |
5.4 |
|
histology |
alveolar |
0 |
|
|
nonalveola |
42.4 |
|
nodal status |
Nx |
0 |
|
|
N0 |
74.1 |
|
|
N1 |
11.2 |
|
tumor site |
favorable |
46 |
|
|
unfavorable |
0 |
|
tumor size |
< 5 cm |
67.9 |
|
|
>= 5 cm |
0 |
|
recurrence |
local |
100 |
|
|
metastatic |
0 |
|
radiotherapy |
no |
85.7 |
|
|
yes |
0 |
|
time to relapse |
>= 1.5 years |
36.6 |
|
|
< 1.5 years |
0 |
total score =
= SUM(points for all 8 parameters)
Interpretation:
• minimum score: 0
• maximum score: 536
• The higher the score the greater the chances of cure after salvage therapy
|
Total Score |
Percent of Patients Achieving Cure |
|
< 21 |
< 1% |
|
21 to 138 |
(0.03433 * (points)) + 0.262 |
|
138 to 286 |
(0.000543 * ((points)^2)) - (0.0601*(points)) + 2.205 |
|
286 to 374 |
(0.3408 * (points)) - 67.73 |
|
374 to 536 |
(-0.000802 * ((points)^2)) + (0.9383 * (points)) - 178.9 |
Specialty: Hematology Oncology, Surgery, general, Surgery, orthopedic
